Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Difenidol is a small molecule antivertigo and antiemetic agent. It is primarily indicated for the treatment of vertigo resulting from conditions such as Meniere's disease or surgery on the middle and inner ear. It is also used to control nausea and vomiting associated with various conditions and to prevent motion sickness. The drug's mechanism of action involves the inhibition of the vestibular system and the chemoreceptor trigger zone (CTZ) in the medulla, likely through muscarinic acetylcholine receptor antagonism. It also improves blood flow in the vertebral artery. Originally developed by Smith, Kline & French as Vontrol, it is now widely produced by various manufacturers, particularly in Asia, where it is often marketed as Cephadol.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on difenidol.